Clinical Trial Update: Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating rilzabrutinib for chronic spontaneous urticaria in patients with persistent symptoms despite H1 antihistamines has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Rilzabrutinib (rilzabrutinib)

Snippet

Sponsor: Sanofi | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED